Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:CHRONYSE:CVMNASDAQ:PMCBOTCMKTS:PMCBD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCHROChromocell Therapeutics$1.19-4.6%$1.19$0.45▼$3.80$7.85M3.22436,328 shs22,372 shsCVMCEL-SCI$2.29-1.3%$5.56$1.98▼$66.60$6.94M0.2773,092 shs2.09 million shsPMCBNuvilex$1.06$1.11$1.00▼$2.42$7.28M-0.4419,495 shs8,755 shsPMCBDPharmaCyte Biotech$1.01$1.12$5.56▼$55.50$1.69M0.278,831 shs16,598 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCHROChromocell Therapeutics+2.25%-3.37%+24.75%-21.54%-0.99%CVMCEL-SCI-7.20%-4.13%-65.32%-73.13%-93.81%PMCBNuvilex+4.95%-1.85%0.00%-36.90%-52.04%PMCBDPharmaCyte Biotech0.00%-2.88%-4.72%-36.08%-53.46%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCHROChromocell Therapeutics0.9684 of 5 stars0.04.00.00.01.92.50.0CVMCEL-SCI0.1041 of 5 stars0.02.00.00.00.60.00.6PMCBNuvilex0.9025 of 5 stars0.03.00.00.00.60.81.9PMCBDPharmaCyte BiotechN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCHROChromocell Therapeutics 0.00N/AN/AN/ACVMCEL-SCI 0.00N/AN/AN/APMCBNuvilex 0.00N/AN/AN/APMCBDPharmaCyte Biotech 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCHROChromocell TherapeuticsN/AN/AN/AN/A($1.65) per shareN/ACVMCEL-SCIN/AN/AN/AN/A$0.15 per shareN/APMCBNuvilexN/AN/AN/AN/A$3.27 per shareN/APMCBDPharmaCyte BiotechN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCHROChromocell Therapeutics-$7.38M-$1.24N/A∞N/AN/AN/A-453.90%N/ACVMCEL-SCI-$26.92M-$12.61N/AN/AN/AN/A-238.05%-104.65%N/APMCBNuvilex$330K$0.741.43∞N/AN/A0.51%0.35%8/11/2025 (Estimated)PMCBDPharmaCyte Biotech-$3.83MN/A0.00∞N/AN/A-49.09%-43.39%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCHROChromocell TherapeuticsN/AN/AN/AN/AN/ACVMCEL-SCIN/AN/AN/AN/AN/APMCBNuvilexN/AN/AN/AN/AN/APMCBDPharmaCyte BiotechN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCHROChromocell TherapeuticsN/A0.600.60CVMCEL-SCI0.661.071.09PMCBNuvilexN/A14.2114.21PMCBDPharmaCyte BiotechN/A4.904.90Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCHROChromocell Therapeutics77.96%CVMCEL-SCI12.08%PMCBNuvilex34.24%PMCBDPharmaCyte Biotech0.02%Insider OwnershipCompanyInsider OwnershipCHROChromocell Therapeutics16.40%CVMCEL-SCI9.93%PMCBNuvilex10.20%PMCBDPharmaCyte BiotechN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCHROChromocell Therapeutics46.60 million5.04 millionN/ACVMCEL-SCI433.03 million64.67 millionOptionablePMCBNuvilex46.86 million6.16 millionOptionablePMCBDPharmaCyte BiotechN/A1.67 millionN/ANot OptionablePMCBD, CHRO, CVM, and PMCB HeadlinesRecent News About These CompaniesPharmaCyte Biotech (PMCB) Earnings Dates & ReportsSeptember 27, 2024 | investing.comInternational Life Sciences & Biotech ConferenceSeptember 12, 2024 | bisnow.comPMCB Stock Earnings: PharmaCyte Biotech Reported Results for Q3 2024March 19, 2024 | investorplace.comPharmaCyte Biotech Inc (PMCB)February 22, 2024 | investing.com2nd Shareholder Lawsuit Filed Against Biotech CompanyJanuary 16, 2024 | law.comExploring beauty’s biotech frontierOctober 27, 2023 | ft.comThe biotech scorecard for the fourth quarter: 16 stock-moving events to watchOctober 9, 2023 | statnews.comPMCB PharmaCyte Biotech, Inc.May 26, 2023 | seekingalpha.comPharmaCyte Biotech Shares Up 13% to 52-Week High After Cash Tender OfferMay 11, 2023 | marketwatch.comWhy Do So Many Biotech Startups Fail?May 6, 2023 | alleywatch.comBaltimore Biotech NewsApril 28, 2023 | bizjournals.comBiotech Study BreakApril 3, 2023 | princeton.eduBiden sees future in ag biotech; food safety includedApril 3, 2023 | foodsafetynews.comBiotech & HealthMarch 30, 2023 | techcrunch.comAlamance Community College celebrates grand opening of new multi-million dollar Biotech CenterMarch 27, 2023 | wunc.orgTalks Underway to Stop Implementation of Mexican Biotech BanDecember 2, 2022 | fb.orgPharmaCyte Biotech Board of Directors Announces Business Review Committee to Evaluate Opportunities to Optimize Shareholder ValueOctober 7, 2022 | finance.yahoo.comBLACK BIRD BIOTECH INCSeptember 28, 2022 | finanznachrichten.deBharat Biotech's Nasal Vaccine Against Covid-19 Cleared For UseSeptember 14, 2022 | ndtv.comPharmaCyte Biotech Rebukes Iroquois’ Commencement of Consent SolicitationJuly 28, 2022 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePMCBD, CHRO, CVM, and PMCB Company DescriptionsChromocell Therapeutics NYSE:CHRO$1.18 -0.06 (-5.01%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Chromocell Therapeutics Corporation, a clinical-stage biotech company, focuses on the development and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. Its lead compound comprises CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as other fields of neuropathic pain and acute and chronic eye pain. Chromocell Therapeutics Corporation was founded in 2002 and is based in Freehold, New Jersey.CEL-SCI NYSE:CVM$2.29 -0.03 (-1.29%) Closing price 04:00 PM EasternExtended Trading$2.23 -0.06 (-2.45%) As of 06:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers. It is also developing products based on its proprietary technology Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company's product pipeline includes CEL-2000; CEL-4000; and CEL-5000, which are LEAPS-based product candidates in preclinical trials for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.Nuvilex NASDAQ:PMCB$1.06 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$1.04 -0.02 (-1.79%) As of 06:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PharmaCyte Biotech, Inc., a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. The company develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; and license agreements with SG Austria Pte. Ltd. and Austrianova Singapore Pte. Ltd. to use the Cell-in-the-Box technology for cancer treatment. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.PharmaCyte Biotech OTCMKTS:PMCBD$1.01 0.00 (0.00%) As of 06/16/2025PharmaCyte Biotech, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatments for cancer and diabetes. It focuses on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box, which will be used as a platform for the development of treatments for inoperable pancreatic cancer and other solid cancerous tumors, and diabetes. The company was founded on October 28, 1996 and is headquartered in Laguna Hills, CA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Salesforce Raises Prices: 3 Reasons Its Stock Price Will Follow Tesla Bulls and Bears Collide: What Investors Should Know Qualcomm: A Technical Setup Is Emerging, and It's Bullish 330% Returns YTD: Is CoreWeave's Momentum Softening? 3 Catalysts in 7 Days: Archer's Growth Story Just Accelerated Microsoft-OpenAI Rift May Cap Stock Upside Potential Jabil Stock Hits Highs on AI Tailwinds and Strong Buybacks Analyst Downgrades Joby, But Overlooks Major Regulatory Wins Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
